Ranbaxy, GlaxoSmithKline Settle Dispute Over U.S. Patent Covering Valtrex
July 26, 2007
Under an agreement announced today, Indian pharmaceutical company Ranbaxy Laboratories Inc. will be allowed to introduce generic copies of the herpes drug Valtrex in the United States in the latter half of 2009. Ranbaxy will have 180 days of exclusivity to sell the pill here. The arrangement between Ranbaxy and GlaxoSmithKline PLC clears the way for the British drug company to drop the suit it filed in 2003 in a US court to stop Ranbaxy from selling generic copies of Valtrex. GSK's patent on Valtrex is due to expire in the United States and most European countries in 2009. In February, the US Food and Drug Administration approved Ranbaxy's plan to make and market generic Valtrex.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.